References

  1. Martin BR, et al. J Support Oncol. 2004;2(4):305-316.

  2. Di Marzo V, et al. Nature. 2001;410:822-825.

  3. Darmani NA. Pharmacol Biochem Behav. 2001;69:239-249.

  4. Darmani NA. Eur J Pharmacol. 2001;430:49-58.

  5. Darmani NA, et al. Pharmacol Biochem Behav. 2003;75:777-787.

  6. Schlicker E, et al. Trends Pharmacol Sci. 2001;22(11):565-572.

  7. Joy JE, et al, eds. Cannabinoids and animal physiology. In: Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press; 1999:33-81.

  8. Cota D, et al. Int J Obesity. 2003;27:289-301.

  9. Harrold JA, et al. Br J Nutr. 2003;90(4):729-734.

  10. Howlett AC, et al. Pharmacol Rev. 2002;54(2):161-202.

  11. Gerdeman GL, et al. Trends Neurosci. 2003;26(4):184-192.

  12. Lupica CR, et al. Br J Pharmacol. 2004;143:227-234.

  13. Wiley JL, et al. Br J Pharmacol. 2005;145:293-300.

  14. MARINOL® [package insert]. Marietta, GA: Unimed Pharmaceuticals, Inc., a Solvay Pharmaceuticals, Inc. company; 2006.

  15. British Medical Association. Therapeutic Uses of Cannabis. Amsterdam, the Netherlands: Harwood Academic Publishers; 1997.

  16. Navari RM, et al. Expert Opin Emerg Drugs. 2006;11(1):137-151.

Next: — MARINOL and HIV/AIDS
Links Contact Prescribing Information Subscribe to Email Alerts Home

Solvay

© 2006 Solvay Pharmaceuticals, Inc.
Please read our Legal Notices and our Privacy Policy.
Product information provided on this site is intended for US residents only. This information is made available to the public for educational purposes only. It should not be used for diagnosing a health problem or disease. It is not meant to be a substitute for the advice of a physician or other health care provider.